About LDN Research Trust
The LDN Research Trust was set up by a small core of people who have Multiple Sclerosis. The primary aim of the Trust is to initiate Clinical Trials of Low Dose Naltrexone.
Whilst working to raise funds for trials, we have helped over 14,000 people to obtain LDN from a General Practitioner or Neurologist, either through the National Health Service or by private prescription. We have also been able to help people, not just in the UK but in countries throughout Europe, as well as USA, Canada, West Indies, Australia, New Zealand, and others.
The mission of LDN aware is to spread public awareness of LDN worldwide.
Low dose naltrexone, where naltrexone is used in doses approximately one-tenth those used for drug/alcohol rehabilitation purposes, is being used as an "off-label" treatment for certain immunologically-related disorders. The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD.
Sign up to our Newsletter
The LDN 2013 AIIC Conference - 5th October 2013
The LDN 2013 AIIC Conference was a charity event organised by the LDN Research Trust and Mark Drugs, which was held at Harper College, Palatine Illinois on 5th October 2013.
The recording of the conference is now availabe online at the cost of $40 for unlimted viewing,
The conference reviewed, compared and contrasted the most recent data and treatments for a variety of Auto-Immune and Immuno-modulated Conditions.